1. Market Research
  2. > Healthcare Market Trends
  3. > Global Healthcare Analysis & Statistics, October 2019

Global Healthcare Analysis & Statistics, October 2019

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Firstword Pharma

All regions

data types

1-30 of 31 reports

Market Access Impact: Renal Cell Carcinoma (EU5) 2018

Market Access Impact: Renal Cell Carcinoma (EU5) 2018

  • $ 5865
  • Industry report
  • April 2018

Market barriers affect 14 percent of RCC prescriptions in Europe. Is your brand losing out?Despite market barriers only affecting 14 percent of all renal cell carcinoma (RCC) prescriptions in Europe, certain ...

  • Industries : Cancer, Pathology
  • Countries : Europe
Targeted Therapies in Asthma: KOL Insight [2018]

Targeted Therapies in Asthma: KOL Insight [2018]

  • $ 9000
  • Industry report
  • February 2018

Can new biologics breathe fresh competition into the targeted asthma treatment landscape?The severe asthma treatment landscape is evolving. Near-term debates will focus on how best to use currently approved ...

  • Industries : Therapy, Medical Biotechnology, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, North America, United Kingdom
Prostate Cancer: Update Bulletin [January 2018]

Prostate Cancer: Update Bulletin [January 2018]

  • $ 1151
  • Industry report
  • January 2018

This edition presents key opinion leader (KOL) views on recent developments in the prostate cancer market. Topics covered include: Pfizer and Astellas’ announcement in September 2017 that the Phase III ...

  • Industries : Therapy, Cancer, Pharmaceutical
  • Countries : Europe
Alzheimer’s Disease: Update Bulletin [January 2018]

Alzheimer’s Disease: Update Bulletin [January 2018]

  • $ 1151
  • Industry report
  • January 2018

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in Alzheimer’s disease (AD) market, including; ...

  • Industries : Mental Health, Pathology, Therapy
  • Countries : World, North America, Europe
Psoriasis: Update Bulletin [January 2018]

Psoriasis: Update Bulletin [January 2018]

  • $ 1151
  • Industry report
  • January 2018

This edition presents key opinion leader (KOL) views on recent developments in the Psoriasis market. Topics covered include: Initiation of thePhase III BE VIVID trial for UCB’s bimekizumab (CDP-4940); ...

  • Industries : Pathology, Biotechnology
  • Countries : Europe, European Union
Colorectal Cancer: Update Bulletin #1

Colorectal Cancer: Update Bulletin #1

  • $ 1151
  • Industry report
  • December 2017

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the colorectal cancer (CRC) market, including; ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : Europe
Cystic Fibrosis: Update Bulletin #3

Cystic Fibrosis: Update Bulletin #3

  • $ 1151
  • Industry report
  • December 2017

This edition presents world leading key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; expert opinions on Vertex Pharmaceuticals’ regulatory ...

  • Industries : Therapy
  • Countries : United States, Europe, World, European Union
Atopic Dermatitis: Update Bulletin #1

Atopic Dermatitis: Update Bulletin #1

  • $ 1151
  • Industry report
  • December 2017

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the atopic dermatitis (AD) market, including; Vanda Ph ...

  • Industries : Pathology, Medical Biotechnology, Therapy, General Medicine and Specialty Medicine
  • Countries : North America, Europe
Multiple Sclerosis [2017]

Multiple Sclerosis [2017]

  • $ 8658
  • Industry report
  • November 2017

How will Ocrevus reshape the MS treatment landscape?A multitude of recent approvals and launches are changing the way MS is treated, but what does the future hold? Key opinion leaders (KOLs) are excited ...

  • Industries : Health Services
  • Countries : United States, North America
Value Added Services in Cardiometabolic Diseases -- Payer views

Value Added Services in Cardiometabolic Diseases -- Payer views

  • $ 2537
  • Industry report
  • October 2017

Pharma’s Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post ...

  • Industries : Chronic Disease
  • Countries : United States, World, European Union
NPS+ Type 2 Diabetes Mellitus EU5 2017

NPS+ Type 2 Diabetes Mellitus EU5 2017

  • $ 2844
  • Industry report
  • September 2017

Why are some EU5 diabetes brands standing out more than others?There are various options available to European diabetologists and primary care physicians to treat Type 2 Diabetes Mellitus (T2DM). Clearly ...

  • Industries : Health Services
  • Countries : Europe
Market Access Impact (EU5) [CLL]

Market Access Impact (EU5) [CLL]

  • $ 5637
  • Industry report
  • June 2017

How are market barriers moving the goalposts for CLL drugs in Europe?Just how significantly are market barriers skewing prescribing behaviour for CLL drugs in Europe? One drug is clearly popular and others ...

  • Industries : Health Services
  • Countries : Europe
Targeted Therapies in Asthma: KOL Insight: Update Bulletin [April 2017]

Targeted Therapies in Asthma: KOL Insight: Update Bulletin [April 2017]

  • $ 1112
  • Industry report
  • April 2017

This edition presents key opinion leader (KOL) views on recent developments in the targeted asthma treatment marketTopics covered include; GlaxoSmithKline’s (GSK) presentation of new data at the American ...

  • Industries : Therapy
  • Countries : World
Overcoming Market Access Barriers to High Value Drugs

Overcoming Market Access Barriers to High Value Drugs

  • $ 2537
  • Industry report
  • February 2017

DescriptionOvercoming market access barriers to high-value drugsHow can you breakthrough the market access barriers that face high-value oncology and immunotherapy products in the EU5 and US?Pharma faces ...

  • Industries : Cancer
  • Countries : United States, World
Idiopathic Pulmonary Fibrosis (IPF): KOL Insight

Idiopathic Pulmonary Fibrosis (IPF): KOL Insight

  • $ 8379
  • Industry report
  • June 2016

What’s on the KOL ‘wish list’ for the next generation of IPF treatments?Physicians currently only have two options for Idiopathic Pulmonary Fibrosis (IPF) sufferers: how do they decide between them? ...

  • Industries : Health Services, Therapy
  • Countries : United States, North America, Italy
Success in Value Added Services: Delivering Better Patient Outcomes

Success in Value Added Services: Delivering Better Patient Outcomes

  • $ 770
  • Industry report
  • June 2016

Win market share, maximise reimbursement and patient adherence with Value Added ServicesYour competitors are winning market share, improving patient adherence and creating strong partnerships with payers ...

  • Industries : Healthcare
  • Countries : World
Market Access Impact: Renal Cell Carcinoma (EU5)

Market Access Impact: Renal Cell Carcinoma (EU5)

  • $ 5586
  • Industry report
  • May 2016

Market barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand one of them?We researched 8 renal cell carcinoma (RCC) treatments to see what happens to their share of the European ...

  • Industries : Health Services
  • Countries : Europe
Customer Experience (CX) in Physician and HCP Engagement

Customer Experience (CX) in Physician and HCP Engagement

  • $ 770
  • Industry report
  • May 2016

A physician’s good customer experience is your biggest asset!Positive customer engagement with healthcare professionals (HCP) builds loyalty to your brands and trust in your company. In a crowded market, ...

  • Industries : Health Services
  • Countries : World
Trends and Innovations in Companion Diagnostics

Trends and Innovations in Companion Diagnostics

  • $ 770
  • Industry report
  • April 2016

Are companion diagnostics becoming a “must have” for market access? Companion Diagnostics (CDx) are playing an increasingly vital role in market access by supporting product value claims and improving ...

  • Industries : Health Services
  • Countries : United States, World
Medical Affairs Reputations (US): Multiple Sclerosis

Medical Affairs Reputations (US): Multiple Sclerosis

  • $ 7638
  • Industry report
  • July 2015

Compare how well pharma Medical Affairs teams perform and find out which ones physicians rate, in our exclusive report on the Multiple Sclerosis sector. See how well your team stacks up against the competition ...

  • Industries : Health Services
  • Countries : Europe
Medical Affairs Reputations (EU5): Multiple Sclerosis

Medical Affairs Reputations (EU5): Multiple Sclerosis

  • $ 7638
  • Industry report
  • July 2015

Compare how well pharma Medical Affairs teams perform and find out which ones physicians rate, in our exclusive report on the Multiple Sclerosis sector. See how well your team stacks up against the competition ...

  • Industries : Health Services
  • Countries : Europe
Physician Views: Can Intarcia's implantable GLP-1 treatment revolutionise the diabetes market?

Physician Views: Can Intarcia's implantable GLP-1 treatment revolutionise the diabetes market?

  • $ 781
  • Industry report
  • April 2015

Intarcia has previously suggested that it is the highest-valued privately owned biotech company in history. This claim is heavily built around the potential success of ITCA 650; a matchstick-sized, subcutaneous ...

  • Industries : Chronic Disease, Therapy, Pathology
  • Countries : United States, World
Physician Views: Are dermatologists ready for a new class of psoriasis therapies?

Physician Views: Are dermatologists ready for a new class of psoriasis therapies?

  • $ 781
  • Industry report
  • January 2015

Novartis has become the first player to bring to market an interleukin-17A inhibitor, most recently announcing on Monday that the European Commission approved Cosentyx for the treatment of moderate-to-severe ...

  • Industries : Pathology, Medical Biotechnology
  • Countries : United States, Europe, European Union
Physician Views: How do oncologists expect use of Kyprolis will be affected by Amgen's positive ASPIRE data?

Physician Views: How do oncologists expect use of Kyprolis will be affected by Amgen's positive ASPIRE data?

  • $ 701
  • Industry report
  • August 2014

When Amgen paid $10.4 billion for Onyx Pharmaceuticals last fall it did so based on the belief that several ongoing studies would generate the data needed to expand use of Kyprolis into earlier stage ...

  • Industries : Health Services
  • Countries : United States, Europe
Physician Views: Can Biogen Idec gatecrash the haemophilia A market?

Physician Views: Can Biogen Idec gatecrash the haemophilia A market?

  • $ 781
  • Industry report
  • July 2014

The $6 billion global haemophilia market is expected to undergo notable evolution over the next decade, with a key trend being the approval and launch of long-acting recombinant factor (rF) VIII (haemophilia ...

  • Industries : Pathology
  • Countries : World, United States
Physician Views: Is the HER2-positive breast cancer extended adjuvant opportunity big enough to support neratinib's blockbuster forecasts?

Physician Views: Is the HER2-positive breast cancer extended adjuvant opportunity big enough to support neratinib's blockbuster forecasts?

  • $ 781
  • Industry report
  • July 2014

Top-line data from the ExteNET study – which were released earlier this week – appear to establish Puma Biotechnology's neratinib as a viable therapy for use in the extended adjuvant setting for HER2-positive ...

  • Industries : Cancer
  • Countries : World
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?

Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?

  • $ 781
  • Industry report
  • July 2014

Two recent developments appear poised to shift the typical US-based treatment regimen for first-line metastatic colorectal cancer in patients with wild-type KRAS gene mutations: approval of Amgen's Vectibix ...

  • Industries : Cancer, Pathology
  • Countries : United States, World
Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU5?

Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU5?

  • $ 781
  • Industry report
  • July 2014

Uptake and usage of Gilead Sciences' Sovaldi (sofosbuvir) in the US market has been closely tracked since FDA approval last December – but how are physicians based in the EU5 utilising the product?FirstWord ...

  • Industries : Therapy
  • Countries : United States, Europe
Physician Views: Are neurologists ready to embrace gene therapy?

Physician Views: Are neurologists ready to embrace gene therapy?

  • $ 781
  • Industry report
  • June 2014

As recently noted by Forbes, the biotech bull market of 2013 has helped to revive an approach to drug development that had become largely abandoned and pursued by only a few devoted believers. Between ...

  • Industries : Medical Biotechnology, Therapy, Pharmaceutical, Mental Health, Biopharmaceutical, Biopharmaceutical, Pathology
  • Countries : World, United States
Physician Views – Are oncologists ready to embrace real-world data?

Physician Views – Are oncologists ready to embrace real-world data?

  • $ 781
  • Industry report
  • April 2014

As pharma looks to both improve the efficiencies of its operating models and deliver more compelling value propositions to healthcare providers and payers, real-world data has provided the opportunity ...

  • Industries : Health Services
  • Countries : World

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on